BACKGROUND: Associations of inflammation with age-related pathologies are documented; however, it is not understood how changes in inflammation over time impact healthy aging. METHODS: We examined associations of long-term change in C-reactive protein (CRP) and interleukin-6 (IL-6) with concurrent onset of physical and cognitive impairment, subsequent cardiovascular disease (CVD), and mortality in 1,051 participants in the Cardiovascular Health Study All Stars Study. Biomarkers were measured in 1996-1997 and 2005-2006. RESULTS: In 2005-2006, median age was 84.9 years, 63% were women and 17% non-white; 21% had at least a doubling in CRP over time and 23% had at least a doubling in IL-6. Adjusting for demographics, CVD risk factors, and 1996-1997 CRP level, each doubling in CRP change over 9 years was associated with higher risk of physical or cognitive impairment (odds ratio 1.29; 95% confidence interval 1.15, 1.45). Results were similar for IL-6 (1.45; 1.20, 1.76). A doubling in IL-6 change over time, but not CRP, was associated with incident CVD events; hazard ratio (95% confidence interval) 1.34 (1.03, 1.75). Doubling in change in each biomarker was individually associated with mortality (CRP: 1.12 [1.03, 1.22]; IL-6 1.39 [1.16, 1.65]). In models containing both change and 2005-2006 level, only level was associated with CVD events and mortality. CONCLUSIONS: Although increases in inflammation markers over 9 years were associated with higher concurrent risk of functional impairment and subsequent CVD events and mortality, final levels of each biomarker appeared to be more important in determining risk of subsequent events than change over time.
BACKGROUND: Associations of inflammation with age-related pathologies are documented; however, it is not understood how changes in inflammation over time impact healthy aging. METHODS: We examined associations of long-term change in C-reactive protein (CRP) and interleukin-6 (IL-6) with concurrent onset of physical and cognitive impairment, subsequent cardiovascular disease (CVD), and mortality in 1,051 participants in the Cardiovascular Health Study All Stars Study. Biomarkers were measured in 1996-1997 and 2005-2006. RESULTS: In 2005-2006, median age was 84.9 years, 63% were women and 17% non-white; 21% had at least a doubling in CRP over time and 23% had at least a doubling in IL-6. Adjusting for demographics, CVD risk factors, and 1996-1997 CRP level, each doubling in CRP change over 9 years was associated with higher risk of physical or cognitive impairment (odds ratio 1.29; 95% confidence interval 1.15, 1.45). Results were similar for IL-6 (1.45; 1.20, 1.76). A doubling in IL-6 change over time, but not CRP, was associated with incident CVD events; hazard ratio (95% confidence interval) 1.34 (1.03, 1.75). Doubling in change in each biomarker was individually associated with mortality (CRP: 1.12 [1.03, 1.22]; IL-6 1.39 [1.16, 1.65]). In models containing both change and 2005-2006 level, only level was associated with CVD events and mortality. CONCLUSIONS: Although increases in inflammation markers over 9 years were associated with higher concurrent risk of functional impairment and subsequent CVD events and mortality, final levels of each biomarker appeared to be more important in determining risk of subsequent events than change over time.
Authors: L P Fried; N O Borhani; P Enright; C D Furberg; J M Gardin; R A Kronmal; L H Kuller; T A Manolio; M B Mittelmark; A Newman Journal: Ann Epidemiol Date: 1991-02 Impact factor: 3.797
Authors: D G Ives; A L Fitzpatrick; D E Bild; B M Psaty; L H Kuller; P M Crowley; R G Cruise; S Theroux Journal: Ann Epidemiol Date: 1995-07 Impact factor: 3.797
Authors: Jorge R Kizer; Alice M Arnold; Nancy S Jenny; Mary Cushman; Elsa S Strotmeyer; Diane G Ives; Jingzhong Ding; Stephen B Kritchevsky; Paulo H M Chaves; Calvin H Hirsch; Anne B Newman Journal: J Gerontol A Biol Sci Med Sci Date: 2011-06-09 Impact factor: 6.053
Authors: Andrea L Metti; Howard Aizenstein; Kristine Yaffe; Robert M Boudreau; Anne Newman; Lenore Launer; Peter J Gianaros; Oscar L Lopez; Judith Saxton; Diane G Ives; Stephen Kritchevsky; Abbe N Vallejo; Caterina Rosano Journal: Neurobiol Aging Date: 2015-07-28 Impact factor: 4.673
Authors: Scott D Nash; Karen J Cruickshanks; Ronald Klein; Barbara E K Klein; F Javier Nieto; Rick Chappell; Carla R Schubert; Michael Y Tsai Journal: J Am Geriatr Soc Date: 2013-07-26 Impact factor: 5.562
Authors: Keenan A Walker; B Gwen Windham; Melinda C Power; Ron C Hoogeveen; Aaron R Folsom; Christie M Ballantyne; David S Knopman; Elizabeth Selvin; Clifford R Jack; Rebecca F Gottesman Journal: Neurobiol Aging Date: 2018-04-04 Impact factor: 4.673
Authors: Keenan A Walker; B Gwen Windham; Charles H Brown; David S Knopman; Clifford R Jack; Thomas H Mosley; Elizabeth Selvin; Dean F Wong; Timothy M Hughes; Yun Zhou; Alden L Gross; Rebecca F Gottesman Journal: J Alzheimers Dis Date: 2018 Impact factor: 4.472
Authors: Anne B Newman; Jason L Sanders; Jorge R Kizer; Robert M Boudreau; Michelle C Odden; Adina Zeki Al Hazzouri; Alice M Arnold Journal: Int J Epidemiol Date: 2016-06-06 Impact factor: 7.196
Authors: Douglas A Wolf; Vicki A Freedman; Jan I Ondrich; Christopher L Seplaki; Brenda C Spillman Journal: J Gerontol B Psychol Sci Soc Sci Date: 2015-03-03 Impact factor: 4.077
Authors: Christina M Parrinello; Pamela L Lutsey; Christie M Ballantyne; Aaron R Folsom; James S Pankow; Elizabeth Selvin Journal: Am Heart J Date: 2015-04-18 Impact factor: 4.749
Authors: Candace K McClure; Samar R El Khoudary; Carrie A Karvonen-Gutierrez; Kelly R Ylitalo; Kristin Tomey; Trang VoPham; Barbara Sternfeld; Jane A Cauley; Siobán Harlow Journal: Exp Gerontol Date: 2013-11-07 Impact factor: 4.032
Authors: Andrea L Metti; Kristine Yaffe; Robert M Boudreau; Eleanor M Simonsick; Ryan M Carnahan; Suzanne Satterfield; Tamara B Harris; Hilsa N Ayonayon; Caterina Rosano; Jane A Cauley Journal: Neurobiol Aging Date: 2014-06-06 Impact factor: 4.673